Dermata Therapeuticsは,毎週実施するアクネ治療薬 XYNGARI のフェーズ3試験結果に肯定的な反応を示し,迅速な改善と高い安全性を示し,2026年半ばにOTCでの発売を予定しています. Dermata Therapeutics presents positive Phase 3 trial results for its weekly acne treatment, XYNGARI, showing rapid improvement and strong safety, with an OTC launch planned for mid-2026.

Dermata Therapeuticsは,パリの欧州皮膚病学および毒性学学会 (EADV) 2025年会議で,XYNGARITM (DMT310) の臨床試験第3相STAR-1の概要を発表しました. Dermata Therapeutics announced the presentation of an abstract from its Phase 3 STAR-1 clinical trial for XYNGARI™ (DMT310), a once-weekly topical treatment for moderate-to-severe acne, at the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris. 2025年9月16日に発表される要約では,炎症性および非炎症性の損傷が早めに4週にわたって大幅に減少し,安全性に関する好ましい結果と治療に関連する深刻な副作用は認められない. The abstract, set for release on September 16, 2025, highlights significant reductions in both inflammatory and non-inflammatory acne lesions as early as Week 4, with favorable safety results and no serious treatment-related adverse events. 同社は2026年半ばに非処方薬のニキビキットも発売する予定です. The company also plans to launch an over-the-counter acne kit in mid-2026.